Cargando…

Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes

INTRODUCTION: The aim of this meta-analysis was to investigate the impact of rapid-acting insulin analogues (RAIAs) and regular human insulin (RHI) on glycemic control, including long- and short-term glycemic variability as measured by glycated haemoglobin (HbA1c) and pre- and postprandial glucose (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nicolucci, Antonio, Ceriello, Antonio, Di Bartolo, Paolo, Corcos, Antonella, Orsini Federici, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048883/ https://www.ncbi.nlm.nih.gov/pubmed/31873857 http://dx.doi.org/10.1007/s13300-019-00732-w

Ejemplares similares

Glycemic Effects of Once-a-Day Rapid-Acting Insulin Analogue Addition on a Basal Insulin Analogue in Korean Subjects with Poorly Controlled Type 2 Diabetes Mellitus
por: Choe, Eun Yeong, et al.
Publicado: (2012)

Subcutaneous fast-acting insulin analogues, alone or in combination with long-acting insulin, versus intravenous regular insulin infusion in patients with diabetic ketoacidosis: protocol for an updated systematic review and meta-analysis of randomised trials
por: Lim, Beng Leong, et al.
Publicado: (2023)

Glargine insulin: an alternative to regular insulin for glycemic control in critically ill patients
por: Bhattacharyya, M, et al.
Publicado: (2007)

Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis
por: Melo, Karla F. S., et al.
Publicado: (2019)

Use of fast‐acting insulin aspart in insulin pump therapy in clinical practice
por: Evans, Mark, et al.
Publicado: (2019)

Regular insulin, rather than rapid‐acting insulin, is a suitable choice for premeal bolus insulin in lean patients with type 2 diabetes mellitus
por: Kuroda, Akio, et al.
Publicado: (2013)

Premeal Injection of Rapid-Acting Insulin Reduces Postprandial Glycemic Excursions in Type 1 Diabetes
por: Luijf, Yoeri M., et al.
Publicado: (2010)

A nationwide cohort study for comparative vascular safety of long-acting insulin analogue versus intermediate-acting human insulin in type 2 diabetes
por: Yang, Chun-Ting, et al.
Publicado: (2021)

Molecular Characterisation of Long-Acting Insulin Analogues in Comparison with Human Insulin, IGF-1 and Insulin X10
por: Hansen, Bo F., et al.
Publicado: (2012)

Human Insulin Versus Insulin Analogues: A True Companion Forgotten
por: Abdi, Hengameh
Publicado: (2019)

Budget Impact of Long-Acting Insulin Analogues: The Case in Brazil
por: Laranjeira, Fernanda O, et al.
Publicado: (2016)

Replacement of neutral protamine Hagedorn insulin with the long‐acting insulin analogue, detemir, improves glycemic control without weight gain in basal–bolus insulin therapy in Japanese patients with type 1 diabetes
por: Hayakawa, Taro, et al.
Publicado: (2011)

Diabetes Interactive Diary: A New Telemedicine System Enabling Flexible Diet and Insulin Therapy While Improving Quality of Life: An open-label, international, multicenter, randomized study
por: Rossi, Maria C.E., et al.
Publicado: (2010)

Safety and Effectiveness of an Investigational Insulin Delivery Device Providing Basal/Bolus Therapy with Rapid-Acting or Regular Human Insulin in Adults with Type 2 Diabetes
por: Aronson, Ronnie, et al.
Publicado: (2020)

Potential Role of Ultrafast-acting Insulin Analogues in the Treatment of Diabetic Ketoacidosis
por: Koufakis, Theocharis, et al.
Publicado: (2022)

Degludec: the new ultra-long insulin analogue
por: Tambascia, Marcos Antonio, et al.
Publicado: (2015)

Glargine versus regular insulin protocol in feline diabetic ketoacidosis
por: Zeugswetter, Florian K., et al.
Publicado: (2021)

Efficacy, safety and cost-effectiveness comparison between U-100 human regular insulin and rapid acting insulin when delivered by V-Go wearable insulin delivery device in type 2 diabetes
por: Mora, Pablo F, et al.
Publicado: (2020)

Comparison of Glycemic Control between Continuous Regular Insulin Infusion and Single-dose Subcutaneous Insulin Glargine Injection in Medical Critically Ill Patients
por: Bhurayanontachai, Rungsun, et al.
Publicado: (2018)

Engineering of Insulin Receptor Isoform-Selective Insulin Analogues
por: Glendorf, Tine, et al.
Publicado: (2011)

Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects
por: de la Peña, Amparo, et al.
Publicado: (2011)

HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target
por: Ceriello, Antonio, et al.
Publicado: (2022)

Lipodistrophy and Associated Risk Factors in Insulin-Treated People With Diabetes
por: Gentile, Sandro, et al.
Publicado: (2016)

Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function
por: Hartmann, Thorsten, et al.
Publicado: (2016)

Glycemic Variability: Both Sides of the Story
por: Ceriello, Antonio, et al.
Publicado: (2013)

Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine
por: Miao, Raymond, et al.
Publicado: (2013)

Therapeutics of Diabetes Mellitus: Focus on Insulin Analogues and Insulin Pumps
por: Valla, Vasiliki
Publicado: (2010)

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
por: Kalra, Sanjay
Publicado: (2014)

Changing the approach to type 2 diabetes treatment: A comparison of glucagon‐like peptide‐1 receptor agonists and sulphonylureas across the continuum of care
por: Orsini Federici, Marco, et al.
Publicado: (2021)

Rapid-acting and Regular Insulin are Equal for High Fat-Protein Meal in Individuals with Type 1 Diabetes Treated with Multiple Daily Injections
por: Jabłońska, Karolina, et al.
Publicado: (2018)

Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
por: Bode, Bruce W., et al.
Publicado: (2017)

OR30-02 Efficacy and Safety Comparison Between U100 Regular Human Insulin and U100 Rapid Acting Insulin When Delivered by a 24 Hour Wearable Insulin Delivery Device in Type 2 Diabetes
por: Mora, Pablo, et al.
Publicado: (2020)

Comparison of Costs and Utilization Between Users of Insulin Lispro Versus Users of Regular Insulin in a Managed Care Setting
por: Chen, Kristina, et al.
Publicado: (2005)

Glycemic Control and Awareness of Insulin Therapy
por: Pashchenko, Yegor, et al.
Publicado: (2021)

Ultra-Rapid-Acting Insulins: How Fast Is Really Needed?
por: Wong, Eva Y., et al.
Publicado: (2021)

Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications
por: Godman, Brian, et al.
Publicado: (2021)

Chymotrypsin substrate analogues inhibit endocytosis of insulin and insulin receptors in adipocytes
Publicado: (1986)

Production costs and potential prices for biosimilars of human insulin and insulin analogues
por: Gotham, Dzintars, et al.
Publicado: (2018)

Cardioprotective role of insulin: Advantage analogues
por: Maiti, Rituparna, et al.
Publicado: (2012)

Safety and Efficacy of Modern Insulin Analogues
por: Yoo, Hye Jin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0o4e0c3e06ssbn9rsd7qq6fcbq